Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAdvanced Biomed Inc. Common Stock

Advanced Biomed Inc. Common Stock

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
1.9 USD -0.20 ( 9.52%)
Last update at 2026-11-05T21:00:00Z
VOLUME
34991
Market Cap
13.35M
P/E
2.02

Momentum Score

…

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.80
Low
2.17
High
52 Week Price Range
3.61
Low
24.23
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.10
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
71.33%
Net Debt
-2902.65M
ROCE
-0.00%
Diluted EPS TTM
4.00

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.10M -2.78M -3.73M -4.03M -1.84M
Net income -0.10M -2.78M -3.73M -4.03M -1.84M
Selling general administrative 2111.26M 1.26M 1.32M 0.62M 0.04M
Gross profit -0.01M -0.01M -0.01M -0.00M -0.00M
Reconciled depreciation - 0.40M 0.37M 0.13M 0.06M
Ebit -0.10M -2.54M -3.07M -2.37M -1.84M
Ebitda -0.09M -2.14M -2.71M -2.24M -1.78M
Depreciation and amortization 0.01M 0.40M 0.37M 0.13M 0.06M
Operating income -0.09M -2.54M -3.07M -2.37M -1.84M
Other operating expenses 0.09M 2.54M 3.07M 2.37M 1.84M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.05M 0.02M 0.00M 0.00M
Net interest income - 0.05M 0.02M 0.00M 0.00M
Total revenue - 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.08M 2.54M 3.07M 2.37M 1.84M
Cost of revenue 0.01M 0.01M 0.01M 0.00M 0.00M
Total other income expense net -0.01M -0.24M -0.66M -1.65M -0.00M
Net income from continuing ops - -2.78M -3.73M -4.03M -1.84M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 6512.34M 4.46M 4.60M 6.71M 1.01M
Intangible assets - 0.12M 0.25M 0.41M -
Other current assets 3128.65M 0.44M 0.16M 0.22M 0.85M
Total liab 3034.78M 2.80M 3.29M 3.22M 0.03M
Total stockholder equity 3477.56M 1.66M 1.31M 3.49M 0.98M
Other current liab 2887.99M 2.05M 2.42M 1.98M 0.02M
Common stock 21.64M 0.02M 0.02M 0.10M 0.01M
Capital stock - 0.02M 0.02M 0.10M 0.01M
Retained earnings -19233.04M -15.97M -13.19M -9.46M -5.43M
Cash 2903.91M 2.61M 2.62M 4.78M 0.07M
Total current liabilities 2889.13M 2.73M 3.28M 2.99M 0.03M
Net debt -2902.65M -2.48M -2.38M -4.31M -0.06M
Short term debt 1.12M 0.06M 0.22M 0.24M 0.01M
Short long term debt total 1.26M 0.13M 0.24M 0.48M 0.01M
Other stockholder equity 21348.01M 16.49M 13.67M 12.58M 6.57M
Total current assets 6032.57M 3.05M 2.79M 5.01M 0.91M
Net receivables 0.01M 0.01M 0.00M 0.16M 0.00M
Inventory - -0.01M - - -
Accounts payable 0.02M 0.62M 0.63M 0.76M 0.00M
Accumulated other comprehensive income 1341.69M 1.12M 0.80M 0.27M -0.18M
Non currrent assets other 414.37M 0.64M 0.61M 0.07M -
Non current assets total 479.77M 1.41M 1.81M 1.71M 0.09M
Capital lease obligations - 0.13M 0.24M 0.47M 0.01M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.07M -0.26M -1.08M -0.03M
Total cashflows from investing activities -0.00M -0.07M -0.26M -1.08M -0.03M
Net borrowings - 1.66M 0.00M - -
Total cash from financing activities 0.18M 1.87M 0.46M 6.10M 0.70M
Net income -0.10M -2.78M -3.73M -4.03M -1.84M
Change in cash 0.02M -0.01M -2.16M 4.72M 0.00M
Begin period cash flow 0.08M 2.62M 4.78M 0.07M 0.07M
End period cash flow 0.10M 2.61M 2.62M 4.78M 0.07M
Total cash from operating activities -0.18M -2.13M -2.96M -0.74M -0.47M
Issuance of capital stock - 0.00M 1.01M 6.10M 0.70M
Depreciation 0.01M 0.40M 0.37M 0.13M 0.06M
Other cashflows from investing activities - - -0.00M -0.39M -
Change to account receivables - 0.05M 0.02M 0.00M 0.00M
Other cashflows from financing activities - 0.21M -0.55M - -
Capital expenditures 0.00M 0.07M 0.21M 1.31M 0.03M
Change in working capital -0.09M 0.26M 0.25M 1.50M 1.31M
Other non cash items 2915.05M -0.05M 0.15M 1.66M -0.00M
Free cash flow -0.18M -2.20M -3.18M -2.05M -0.50M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
ADVB
Advanced Biomed Inc. Common Stock		 -0.20
9.52%		 1.90 2.02 - - 1.38
TMO
Thermo Fisher Scientific Inc		 -29.22
4.14%		 676.94 34.71 23.87 4.62 4.43
DHR
Danaher Corporation		 -8.59
3.66%		 226.34 29.09 28.01 5.67 3.20
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 26.96 22.29 17.95 1.53 5.98
WUXAY
WuXi AppTec Co. Ltd		 0.44
1.75%		 25.55 23.28 18.73 1.51 6.24

Profile*

Advanced Biomed Inc. Common Stock

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

122 East 42nd Street, New York, NY, United States, 10168

https://www.advanbiomed.com

31

Name Title Year Born
Dr. Yi Lu Ph.D. CEO & Chairman 1965
Mr. Mingze Yin CFO & Director 1990
- Alan Director of Investor Relations NA
Dr. Hung To Pau Ph.D. Secretary 1974
Mr. Mingze Yin CFO & Director 1989
Mr. Xiaomin Chen Ph.D. CEO & Chairman 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…